@entity65 in @entity1 with XXXX exposed to androgen deprivation therapy.

@entity1 @entity712 @entity263 @entity1176 @entity209 @entity583 @entity65
INTRODUCTION: A relationship between the administration of @entity1176 agonists and the risk of @entity583 ( @entity583 ) in @entity1 with @entity263 has been showed in the third observational study published in April 2014. The association @entity583 -orchiectomy was not found in any of these studies. OBJECTIVE: Define risk factors for @entity65 in @entity1 treated with @entity1176 agonist. Their probable underlying pathogenic mechanism in the myocardium and peripheral vascular tree was also analyzed. EVIDENCE ACQUISITION: English articles cited in PubMed were reviewed. No time period is specified. The last search date was 11/30/14. EVIDENCE SYNTHESIS: In @entity1 with coronary history of @entity583 or @entity712 , hormonal neoadjuvant therapy increased cardiovascular mortality rates (HR: 1.96, IC 95%: 1.04-3.71; P=.04) as well as cardiovascular-specific mortality rates (AHR: 3.28; IC 95%: 1.01-10.64; P=.048). Two possible mechanisms can be involved: a) direct mechanism through myocardial receptor for @entity1176 /PKA along with atherogenic plaques; and b) indirect mechanism related with @entity209 . CONCLUSIONS: @entity1 with @entity583 or @entity712 history could present a higher risk of death related to the use of @entity1176 agonists. In these cases, should carefully consider appropriateness of such treatment. These effects can explained by a direct mechanism on myocardium and peripheral vascular tree and indirect ones related with modified @entity209 .
